|1.||Gasior, Maciej: 1 article (05/2011)|
|2.||Gruner, John A: 1 article (05/2011)|
|3.||Mathiasen, Joanne R: 1 article (05/2011)|
|4.||Flood, Dorothy G: 1 article (05/2011)|
|5.||Bashkatova, V: 1 article (06/2002)|
|6.||Penit-Soria, J: 1 article (06/2002)|
|7.||Durand, C: 1 article (06/2002)|
|8.||Mathieu-Kia, A-M: 1 article (06/2002)|
|9.||Salenko, Iu A: 1 article (05/2000)|
|10.||Morozov, I S: 1 article (05/2000)|
|1.||Syringomyelia (Morvan's Disease)
05/01/2000 - "Bromantan increases the tension of motivational component (electric pain irritation avoidance), whereas sydnocarb decreases this component of the operant behavior. "
01/01/1994 - "When their combination was used, the clinical signs of the pain syndrome developed in the same way as with sydnocarb alone. "
10/01/1987 - "The absence of sydnocarb-induced pain threshold decrease in response to electrical pain stimulation suggests a direct drug effect on memory processes."
01/01/1994 - "Sydnocarb arrested the progression of the pain syndrome, reduced its symptoms, alleviated inflammatory manifestations and extremity edema. "
01/01/1994 - "[The effect of fenazepam and sidnocarb in the phantom pain syndrome]."
|5.||Schizophrenia (Dementia Praecox)
03/01/1999 - "Sydnocarb (3-(beta-phenylisopropyl)-N-phenylcarbamoylsydnonimine) is a psychostimulant in clinical practice in Russia as a primary and adjunct therapy for a host of psychiatric disorders, including schizophrenia and depression. "
06/01/2002 - "Sydnocarb [(phenylisopropyl)N-phenylcarbamoylsydnonimine; SYD] was introduced to clinical practice in Russia as a psychostimulant drug used for the treatment of asthenia and apathy, which accompany schizophrenia and manic depression. "
|3.||Neurotransmitter Agents (Neurotransmitter)
|5.||gamma-Aminobutyric Acid (GABA)